57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia

Key Takeaways Explain This Topic AI

The primary pathophysiology of GERD is transient lower esophageal sphincter relaxations (TLESRs); initial empiric management for typical heartburn or regurgitation without alarm features is an 8-week trial of once-daily PPI taken 30 to 60 minutes before the first meal of the day.

Upper endoscopy (EGD) is strictly indicated in the presence of alarm features (dysphagia, odynophagia, unexplained weight loss, hematemesis, melena, iron deficiency anemia, persistent vomiting) at any age, or upon failure of symptom response after 8 weeks of optimized twice-daily PPI therapy.

Long-term PPI therapy carries modest observational associations with osteoporotic hip fractures, Clostridioides difficile colitis, hypomagnesemia, vitamin B12 deficiency, and interstitial nephritis; regular deprescribing evaluations utilizing gradual dose tapering and step-down to H2-receptor antagonists or as-needed therapy are standard of care.

Barrett's esophagus screening is recommended in men with chronic GERD (>5 years) possessing >=2 additional risk factors (age >=50, Caucasian race, central obesity, history of smoking, family history of Barrett's or esophageal adenocarcinoma); non-dysplastic Barrett's requires endoscopic surveillance every 3 to 5 years.

Confirmed low-grade dysplasia warrants endoscopic eradication therapy with radiofrequency ablation (preferred) or surveillance every 6 to 12 months; high-grade dysplasia requires endoscopic mucosal resection of visible mucosal irregularities followed by radiofrequency ablation of the remaining flat Barrett's segment.

Last updated: September 2026

Gastroesophageal Reflux Disease (GERD): Pathophysiology, Clinical Presentation & Initial Therapy

Gastroesophageal reflux disease (GERD) is defined as the retrograde flow of gastroduodenal contents into the esophagus, producing troublesome symptoms and/or mucosal complications. Affecting approximately 20% of the adult population in North America, GERD represents one of the most frequent primary care presentations. Understanding its underlying mechanics, distinguishing typical from atypical presentations, and executing evidence-based management are core family medicine competencies.

Pathophysiologic Mechanisms

The antireflux barrier at the gastroesophageal junction (GEJ) depends on the anatomical alignment and functional integrity of the intrinsic lower esophageal sphincter (LES) smooth muscle and the extrinsic crural diaphragm:

Transient Lower Esophageal Sphincter Relaxations (TLESRs) :

The predominant pathophysiologic mechanism in patients with mild-to-moderate, non-erosive GERD.

TLESRs are physiologic, vasovagal reflexes triggered by gastric fundic distention that allow swallowed air to vent (physiologic belching). In GERD, TLESRs occur with increased frequency, last longer (often >10 to 35 seconds), and are more frequently accompanied by retrograde acid and pepsin reflux.

Hypotensive Lower Esophageal Sphincter :

Abnormally low basal LES resting pressure (<10 to 15 mmHg; normal is 15 to 30 mmHg).

Allows free "stress reflux" during acute elevations in intra-abdominal pressure (e.g., coughing, straining, bending forward).

Hiatal Hernia (Type I Axial / Sliding Hernia) :

Migration of the GEJ and gastric cardia through the esophageal diaphragmatic hiatus into the posterior mediastinum.

Disrupts the normal high-pressure zone by dissociating the intrinsic LES from the extrinsic diaphragmatic pinchcock mechanism. The herniated gastric pouch serves as an acidic reservoir that easily refluxes during swallowing and delays esophageal acid clearance.

Impaired Esophageal Clearance & Acid Buffering :

Defective secondary peristalsis fails to strip refluxed liquid back into the stomach.

Decreased salivary production (saliva contains bicarbonate and epidermal growth factor) diminishes chemical neutralization of luminal acid.

Delayed Gastric Emptying (Gastroparesis) :

Elevated intragastric volume increases postprandial wall tension, stimulating excessive TLESRs and promoting acid overflow.

The Gastric "Acid Pocket" :

A unbuffered pool of highly acidic (pH 1.5 to 2.0) gastric juice that forms on top of chyme in the gastric fundus immediately after eating, directly positioned at the vulnerable GEJ.

Clinical Presentation: Typical vs. Extraesophageal Symptoms CLINICAL SPECTRUM OF GERD SYMPTOMS

• Category Signs and Symptoms & Pathophysiology
• ═════════════════════════════════════════════════════════════════════════════
• Typical Symptoms • Heartburn (pyrosis): Substernal burning discomfort
• radiating upward toward the neck, exacerbated by meals,
• bending over, or lying supine
• Acid Regurgitation: Effortless return of sour, bitter
• gastric contents into the pharynx or mouth
• Water Brash: Sudden reflex salivation induced by acid
• irritation of the lower esophageal mucosa

• Atypical / • Chronic Cough: Secondary to vagally mediated esophageal-
• Extraesophageal bronchial neural reflex or microaspiration into larynx
• Symptoms • Adult-Onset Asthma / Nocturnal Wheezing: Reflex
• bronchospasm triggered by acid fumes
• Reflux Laryngitis: Morning hoarseness, throat clearing,
• posterior laryngitis (arytenoid erythema/edema)
• Globus Sensation: Persistent feeling of a lump or fullness
• in the throat unrelated to swallowing
• Dental Erosions: Acid dissolution of lingual and palatal
• enamel surfaces (often identified by dentists)
• Non-Cardiac Chest Pain: Squeezing retrosternal pain
• mimicking acute coronary syndrome; requires cardiac
• clearance before attributing exclusively to GERD
• ═════════════════════════════════════════════════════════════════════════════
• Lifestyle Interventions: Evidence-Based Recommendations

Non-pharmacologic lifestyle interventions constitute the essential foundation of GERD management and should be instituted in every patient:

Weight Loss : The single lifestyle intervention with the strongest evidence (Grade A recommendation). Increased central and visceral adiposity elevates intra-abdominal pressure, widens the gastroesophageal pressure gradient, and increases hiatal hernia formation. Weight loss consistently improves esophageal pH profiles and leads to complete resolution of symptoms in up to 40% of overweight or obese individuals.

Head-of-the-Bed Elevation (6 to 8 inches) : Elevating the head of the bed using 6- to 8-inch solid bed risers under the headboard posts or sleeping on a firm medical wedge pillow utilizes gravity to accelerate nocturnal acid clearance and prevent proximal reflux. Clinical Pearl : Stacking multiple standard bed pillows is completely ineffective and counterproductive, as it flexes the neck and waist, increasing intra-abdominal pressure.

Avoid Late-Night Meals : Refraining from food and caloric liquids for at least 2 to 3 hours before lying recumbent ensures substantial gastric emptying prior to sleep, eliminating the recumbent postprandial acid pocket.

Left Lateral Decubitus Positioning : Sleeping on the left side positions the GEJ above the level of gastric contents, decreasing nocturnal reflux events compared to right lateral or prone positioning.

Dietary Modification : While evidence for universal dietary restriction is variable, patients should identify and eliminate personal triggers that relax the LES (chocolate, peppermint, caffeine, alcohol, high-fat meals) or cause direct mucosal irritation (citrus, tomato-based sauces, spicy foods, carbonated beverages).

Tobacco and Alcohol Cessation : Nicotine and ethanol directly reduce basal LES tone, impair salivary secretion, and blunt esophageal clearance.

First-Line Pharmacotherapy: Empiric PPI Trial

In patients presenting with typical GERD symptoms (heartburn and regurgitation) without alarm features, clinical practice guidelines from the American College of Gastroenterology (ACG) and American Gastroenterological Association (AGA) recommend an empiric 8-week trial of once-daily Proton Pump Inhibitor (PPI) therapy:

First-Line Agents and Standard Dosages :

• Omeprazole 20 to 40 mg PO once daily
• Pantoprazole 40 mg PO once daily
• Esomeprazole 20 to 40 mg PO once daily
• Lansoprazole 30 mg PO once daily

Crucial Administration Timing Rule :

PPIs are prodrugs requiring an acidic environment for bioactivation inside the secretory canaliculus of the gastric parietal cell. Once activated, they form a covalent disulfide bond with the active H + / K + H^+/K^+ H + / K + ATPase pump, irreversibly inhibiting acid secretion.

Parietal cell proton pumps are newly synthesized and inserted into the luminal membrane primarily in response to food stimulation.

Therefore, PPIs MUST be ingested 30 to 60 minutes before the first meal of the day (typically breakfast) to ensure peak circulating systemic drug concentrations coincide exactly with maximal parietal cell stimulation. Taking a PPI at bedtime, with a meal, or on an empty stomach without subsequent food reduces clinical efficacy by 50% or more.

Therapeutic Escalation :

If symptoms show an incomplete response after 4 to 8 weeks of once-daily therapy, the dosage should be optimized to twice-daily PPI therapy (taken 30 to 60 minutes before breakfast and 30 to 60 minutes before dinner).

Indications for Upper Endoscopy, Alarm Features & PPI Safety Counseling

While empiric PPI therapy is appropriate for uncomplicated typical GERD, indiscriminate PPI prescribing without structural evaluation can delay the detection of esophageal adenocarcinoma, peptic strictures, or severe ulceration.

Alarm Features Requiring Prompt Upper Endoscopy (EGD)

The presence of any alarm feature at any age mandates prompt referral for diagnostic esophagogastroduodenoscopy (EGD) with biopsies:

Dysphagia (Difficulty Swallowing) : Particularly progressive dysphagia (solids progressing to liquids), which strongly suggests mechanical obstruction from a peptic stricture, esophageal web/ring, or esophageal carcinoma. Intermittent dysphagia to both solids and liquids suggests an esophageal motility disorder (achalasia) or eosinophilic esophagitis.

Odynophagia (Painful Swallowing) : Strongly suggests deep mucosal ulceration, severe infectious esophagitis (Candida, CMV, HSV), or pill-induced esophagitis (doxycycline, NSAIDs, bisphosphonates, potassium chloride).

Unintentional Weight Loss : Suggests advanced gastrointestinal malignancy or severe malnutrition.

Overt Gastrointestinal Bleeding : Hematemesis (bright red blood or "coffee-ground" emesis) or melena.

Iron Deficiency Anemia : Unexplained microcytic anemia warrants bi-directional endoscopy (EGD and colonoscopy) to rule out occult GI malignancy or Cameron lesions (ulcerations within a large hiatal hernia).

Persistent Refractory Vomiting : Protracted emesis causing dehydration or electrolyte disturbances.

Palpable Epigastric Mass or Lymphadenopathy : (e.g., Virchow node [left supraclavicular] or Sister Mary Joseph nodule [periumbilical]). SUMMARY OF EGD INDICATIONS IN GERD

• Clinical Scenario Endoscopic Recommendation
• ═════════════════════════════════════════════════════════════════════════════════
• Presence of Alarm Features (any age) Prompt diagnostic EGD with biopsies

• Refractory Typical Symptoms EGD indicated after failure of an 8-week
• trial of optimized twice-daily PPI therapy

• Screening for Barrett's Esophagus Men with chronic GERD (>5 yrs) and >=2 risk
• factors (age >=50, Caucasian, central obesity,
• smoking, family history)

• Severe Erosive Esophagitis (LA Grade C or D) Repeat EGD in 8 to 12 weeks after high-dose
• PPI to confirm healing and exclude occult BE
• ═════════════════════════════════════════════════════════════════════════════════
• Long-Term PPI Safety: Evidence-Based Counseling

Proton pump inhibitors are among the most widely prescribed drug classes globally. Although highly effective and generally well-tolerated, chronic long-term hypochlorhydria has been linked in large observational cohorts to several potential adverse outcomes. Family physicians must provide balanced, evidence-grounded risk communication:

Bone Mineral Density Loss and Fragility Fractures :

Gastric acidity is essential for the ionization and solubilization of insoluble dietary calcium carbonate . Chronic hypochlorhydria impairs active calcium absorption, triggering secondary hyperparathyroidism and accelerated bone resorption.

The FDA issued a safety warning regarding an increased risk of osteoporotic hip, wrist, and spine fractures with high-dose or long-term (>1 year) PPI use. In patients requiring prolonged PPIs who need calcium supplementation, recommend calcium citrate , which does not require gastric acidity for absorption.

Enteric Infections & Clostridioides difficile Colitis :

Gastric acid serves as a formidable physiologic barrier against ingested bacterial pathogens. Suppression of gastric acidity enables vegetative spores and bacteria to survive transit into the lower bowel.

PPI use is associated with a 1.5- to 2.5-fold increased risk of Clostridioides difficile-associated diarrhea , as well as increased susceptibility to Campylobacter , Salmonella , and traveler's diarrhea.

Hypomagnesemia :

Prolonged PPI therapy (>1 year) can impair active intestinal magnesium absorption mediated by transient receptor potential melastatin-6 and -7 ( TRPM6/TRPM7 ) ion channels in the enterocyte brush border.

Can present with severe tetany, tremor, refractory hypokalemia, and secondary hypocalcemia (impaired PTH release). Baseline and periodic serum magnesium monitoring is prudent in patients on concurrent diuretics or digoxin.

Vitamin B12 (Cobalamin) Deficiency :

Gastric acid and pepsin are mandatory to cleave dietary vitamin B12 from animal salivary haptocorrins and food proteins before it can bind gastric intrinsic factor. Long-term PPI use (>2 to 3 years) can lead to subclinical B12 malabsorption and macrocytic anemia/neuropathy, particularly in elderly or malnourished patients.

Acute Interstitial Nephritis (AIN) & Chronic Kidney Disease (CKD) :

Rare, idiosyncratic, immune-mediated hypersensitivity reaction presenting with progressive azotemia, eosinophiluria, and sterile pyuria. PPIs must be discontinued immediately if drug-induced AIN is suspected.

Structured PPI Deprescribing Protocol

Routine continuation of PPI therapy without ongoing clinical indication is widespread. Clinicians should conduct annual deprescribing reviews. Except in patients with definitive indications for indefinite therapy (e.g., Los Angeles Grade C/D severe erosive esophagitis, Barrett's esophagus, peptic esophageal stricture, or high GI bleed risk on chronic dual antithrombotics/NSAIDs), deprescribing should be actively pursued:

Preventing Rebound Acid Hypersecretion :

Chronic PPI therapy elevates serum gastrin (hypergastrinemia due to lack of negative feedback inhibition by luminal acid). Hypergastrinemia causes ECL cell hyperplasia and parietal cell hypertrophy.

Abrupt cessation triggers severe rebound acid hypersecretion , producing intense burning symptoms that patients misinterpret as returning underlying disease, leading to drug resumption.

Tapering Regimen :

Step 1 : Halve the daily dose for 2 to 4 weeks (e.g., reduce omeprazole from 40 mg daily to 20 mg daily, or switch twice-daily to once-daily).

Step 2 : Space to alternate-day dosing (every other day) for 2 weeks.

Step 3 : Step-down to an H2-receptor antagonist ( famotidine 20 mg once to twice daily ) or provide on-demand, as-needed PPI/antacid therapy for breakthrough symptoms.

Barrett's Esophagus: Pathogenesis, ACG 2022 Screening & Surveillance Guidelines

Barrett's esophagus (BE) represents a premalignant metaplastic complication of chronic gastroesophageal reflux disease, characterized by the replacement of the normal stratified squamous epithelium of the distal esophagus with specialized columnar epithelium containing intestinal goblet cells.

Pathogenesis & Risk Stratification

Repetitive mucosal acid and bile acid injury damages the squamous lining, triggering an abnormal, reprogrammed stem cell repair process. Columnar cells with alcian blue-positive goblet cells (specialized intestinal metaplasia) are more resistant to acid erosion but carry an inherent genomic instability that can sequentially progress to low-grade dysplasia (LGD), high-grade dysplasia (HGD), and invasive esophageal adenocarcinoma (EAC) . Adenocarcinoma of the esophagus has had the fastest-rising incidence among solid malignancies in Western nations over the last four decades. RISK FACTORS FOR BARRETT'S ESOPHAGUS

• Major Risk Factors Clinical Significance
• ═════════════════════════════════════════════════════════════════════════════
• Chronic GERD Duration Symptoms lasting > 5 years significantly
• elevates metaplastic transformation risk
• Male Sex 3:1 to 4:1 male-to-female predominance
• Age >= 50 Years Incidence peaks in the 6th and 7th decades
• Caucasian Race Markedly higher prevalence than Black or Hispanic
• Central / Visceral Obesity Waist-to-hip ratio correlates more strongly
• than overall BMI with BE and EAC risk
• Tobacco Smoking History Significant independent risk factor for EAC
• Family History First-degree relative with BE or esophageal
• adenocarcinoma doubles to triples individual risk
• ═════════════════════════════════════════════════════════════════════════════
• ACG 2022 Screening Recommendations

The American College of Gastroenterology (ACG) recommends a single screening EGD in men with chronic GERD symptoms (>5 years) who have at least TWO additional risk factors : age >=50 years, Caucasian race, central obesity (waist circumference >102 cm), history of cigarette smoking, or a confirmed family history of BE or EAC in a first-degree relative.

Routine screening in women is NOT recommended due to a very low absolute incidence of EAC, but can be considered if a woman has chronic GERD plus multiple high-risk features.

If a screening EGD is entirely negative for Barrett's esophagus, routine repeat screening is not indicated .

Endoscopic Staging: The Prague Criteria

During endoscopy, the extent of Barrett's esophagus must be rigorously documented using the standardized Prague C & M Criteria :

C Value (Circumferential extent) : The length (in centimeters) of the circumferential columnar metaplasia above the gastroesophageal junction.

M Value (Maximal extent) : The total length (in centimeters) of the maximal tongue or projection of columnar metaplasia above the GEJ.

Example : A Barrett segment extending circumferentially for 2 cm with a tongue extending to 5 cm is staged as Prague C2M5 .

"Short-segment" BE is defined as maximal length <3 cm; "long-segment" BE is >=3 cm. Long-segment BE carries a substantially higher rate of neoplastic progression.

ACG 2022 Surveillance & Treatment Guidelines

Tissue biopsies must follow the standardized Seattle Biopsy Protocol : 4-quadrant mucosal biopsies taken every 1 to 2 cm throughout the entire length of the Barrett segment, plus targeted biopsies of any visible mucosal irregularities, plaques, or ulcerations. ACG 2022 BARRETT'S ESOPHAGUS SURVEILLANCE & THERAPY

• Histologic Staging Annual EAC Risk Evidence-Based Management Pathway
• ═════════════════════════════════════════════════════════════════════════════════════════════
• Non-Dysplastic 0.1% to 0.3% / yr Surveillance EGD with 4-quadrant biopsies
• Barrett's Esophagus (NDBE) every 3 to 5 years; optimize daily PPI therapy

• Indeterminate for Variable Optimize acid suppression with TWICE-DAILY
• Dysplasia PPI therapy for 3 to 6 months to resolve active
• inflammation, then REPEAT EGD with biopsies

• Low-Grade Dysplasia 0.5% to 1.4% / yr 1. MUST be confirmed by TWO expert GI pathologists
• (LGD) 2. Preferred: Endoscopic Eradication Therapy
• (Radiofrequency Ablation [RFA])
• 3. Alternative: Surveillance EGD every 6 to 12 months

High-Grade Dysplasia 5% to 7% / yr 1. MUST be confirmed by TWO expert GI pathologists

(HGD) 2. Endoscopic Eradication Therapy:

• Endoscopic Mucosal Resection (EMR) for any
• visible nodules / mucosal irregularities
• Radiofrequency Ablation (RFA) of remaining
• flat Barrett mucosa
• 3. Follow-up surveillance EGD every 3 months
• ═════════════════════════════════════════════════════════════════════════════════════════════

Endoscopic Eradication Therapy (EET) :

Radiofrequency Ablation (RFA - Barrx) : Delivers controlled thermal energy to a precise mucosal depth (500 to 1,000 micrometers), coagulating the dysplastic metaplastic epithelium down to the muscularis mucosae without damaging the underlying submucosa, allowing healthy squamous epithelium to regenerate under high-dose acid suppression.

Endoscopic Mucosal Resection (EMR) : Uses suction or band ligation with a snare to excise discrete mucosal nodules or elevated lesions. EMR provides critical full-thickness mucosal histopathology to rule out invasive submucosal (T1b) adenocarcinoma. Any visible lesion in a dysplastic Barrett segment must undergo EMR before applying RFA to the remaining flat segment.

Surgical Esophagectomy : Formerly standard for HGD, esophagectomy is now reserved strictly for invasive submucosal adenocarcinoma (T1b or deeper) with lymphovascular invasion, poorly differentiated histology, or lesions refractory to endoscopic ablation.

Dyspepsia: Differential Diagnosis, Rome IV Criteria & Algorithmic Evaluation

Dyspepsia is defined as one or more symptoms referable to the gastroduodenal region: postprandial fullness, early satiety, and epigastric pain or epigastric burning. In primary care, the initial management hinges upon patient age, the presence of alarm signs, and non-invasive Helicobacter pylori testing.

Functional Dyspepsia & Rome IV Diagnostic Criteria

Functional dyspepsia (FD) is diagnosed when symptoms have persisted for at least 3 months, with symptom onset at least 6 months prior, and routine diagnostic evaluation (including EGD) fails to reveal an organic structural etiology. Rome IV subdivides FD into two distinct clinical phenotypes:

Postprandial Distress Syndrome (PDS) : Characterized by bothersome postprandial fullness (inability to finish a normal-sized meal) and early satiety occurring at least 3 days per week. Pathophysiology involves impaired gastric fundic accommodation and delayed gastric emptying. First-line therapies include dietary modification (small, low-fat, frequent meals) and prokinetic agents (e.g., metoclopramide short-term or buspirone to improve fundic accommodation).

Epigastric Pain Syndrome (EPS) : Characterized by bothersome, well-localized epigastric pain or burning occurring at least 1 day per week, not exclusively postprandial and not relieved by defecation. First-line medical therapy is an empiric trial of a PPI or H2RA. EVIDENCE-BASED DYSPEPSIA CLINICAL ALGORITHM

• Patient Presents with Uninvestigated Dyspepsia
• (Epigastric pain, burning, postprandial fullness, early satiety)
• │
• ┌───────────────┴───────────────┐
• ▼ ▼
• Age >= 60 Years OR Alarm Features Age < 60 Years AND No Alarm Features
• (Dysphagia, weight loss, bleeding, │
• vomiting, anemia, family hx) ▼
• │ Non-Invasive H. pylori Testing
• ▼ (Urea Breath Test or Stool Antigen)
• PROMPT UPPER ENDOSCOPY (EGD) │
• with Gastric Biopsies ┌────────┴────────┐
• ▼ ▼
• POSITIVE NEGATIVE
• │ │
• ▼ ▼
• 14-Day Bismuth Empiric PPI Trial
• Quadruple Therapy (4 to 8 Weeks)
• + Confirm Cure │
• ▼

If Ineffective:

• Trial Neuromodulator
• (Low-dose TCA e.g.,
• Nortriptyline)
• Clinical Management Rules for Dyspepsia

The Age 60 Threshold : According to the joint ACG/CAG guidelines, the age threshold for performing mandatory initial diagnostic EGD in uninvestigated dyspepsia (without alarm features) is 60 years (reduced from 65 in prior iterations), based on the exponential rise in gastric and esophageal malignancy beyond this age.

H. pylori Test-and-Treat Strategy : For patients <60 years of age without alarm features , the standard evidence-based strategy is non-invasive H. pylori testing utilizing the urea breath test (UBT) or laboratory-based stool antigen enzyme immunoassay . Serologic antibody testing is strictly obsolete due to poor specificity and inability to distinguish active from cleared infection.

Pre-Test Washout Rules : Before performing UBT or stool antigen testing, PPIs must be withheld for at least 2 weeks , and antibiotics and bismuth compounds must be withheld for at least 4 weeks to eliminate false-negative results. H2-receptor antagonists and antacids do not interfere with test accuracy.

Neuromodulators in Refractory Functional Dyspepsia : In patients with functional dyspepsia who fail both H. pylori eradication and high-dose PPI therapy, low-dose tricyclic antidepressants (TCAs) , such as nortriptyline (10 to 25 mg at bedtime) or amitriptyline, provide significant symptom relief by blunting visceral hypersensitivity and modulating central pain processing.

Loading diagram... Evidence-Based Diagnostic & Surveillance Algorithm for GERD and Barrett's Esophagus